Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bicycle Therapeutics plc before investing.

In this article, we go over a few key elements for understanding Bicycle Therapeutics plc’s stock price such as:

• Bicycle Therapeutics plc’s current stock price and volume
• Why Bicycle Therapeutics plc’s stock price changed recently
• Upgrades and downgrades for BCYC from analysts
• BCYC’s stock price momentum as measured by its relative strength

About Bicycle Therapeutics plc (BCYC)

Before we jump into Bicycle Therapeutics plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Want to learn more about Bicycle Therapeutics plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bicycle Therapeutics plc.

Bicycle Therapeutics plc’s Stock Price as of Market Close

As of April 29, 2026, 4:00 PM, CST, Bicycle Therapeutics plc’s stock price was $4.730.

Bicycle Therapeutics plc is up 0.85% from its previous closing price of $4.690.

During the last market session, Bicycle Therapeutics plc’s stock traded between $4.590 and $4.760. Currently, there are approximately 69.36 million shares outstanding for Bicycle Therapeutics plc.

Bicycle Therapeutics plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Bicycle Therapeutics plc Stock Price History

Bicycle Therapeutics plc’s (BCYC) price is currently up 1.94% so far this month.

During the month of April, Bicycle Therapeutics plc’s stock price has reached a high of $5.410 and a low of $4.590.

Over the last year, Bicycle Therapeutics plc has hit prices as high as $9.550 and as low as $4.240. Year to date, Bicycle Therapeutics plc’s stock is down 33.19%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bicycle Therapeutics plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 29, 2026, there were 2 analysts who downgraded Bicycle Therapeutics plc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Bicycle Therapeutics plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bicycle Therapeutics plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Bicycle Therapeutics plc’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bicycle Therapeutics plc (BCYC) by visiting AAII Stock Evaluator.

Relative Price Strength of Bicycle Therapeutics plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 29, 2026, Bicycle Therapeutics plc has a weighted four-quarter relative price strength of -20.00%, which translates to a Momentum Score of 11 and is considered to be Very Weak.

Want to learn more about how Bicycle Therapeutics plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bicycle Therapeutics plc Stock Price: Bottom Line

As of April 29, 2026, Bicycle Therapeutics plc’s stock price is $4.730, which is up 0.85% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bicycle Therapeutics plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.